Abstract

PurposeTo compare CTVHR and OAR dimensions and inter-rater agreement between magnetic resonance (MR) and trans-rectal ultrasound (TRUS) images in IB cervical cancer patients.MethodsIB cervical cancer patients treated with (chemo)radiotherapy plus MR-guided brachytherapy (BT) were prospectively enrolled in this study. Radiation oncologists contoured CTVHR and OARs in pre-BT MR images (MRI) and intra-operative TRUS images. These contours were subsequently compared in regard to volume and dimension. Contour inter-rater agreement analysis was also investigated using kappa index (KI). Stata 15.0 was used for statistical analysis and a p-value < 0.05 was considered statistically significant.ResultsTRUS CTVHR volumes were statistically smaller than the respective MRI contoured volumes. TRUS CTVHR thickness was found to be consistently smaller than MRI contours in all patients. No statistical difference was seen in width and height between the two different imaging modalities. MRI contours had a median KI of 0.66 (range: 0.56–0.77) while TRUS-based contours had a median KI of 0.64 (range: 0.47–0.77). Bladder and rectum had very satisfactory KI in both imaging modalities. Vaginal contours had moderate agreement in MR (0.52) and in TRUS images (0.58).ConclusionTRUS images allow good visualization of CTVHR and OARs in IB cervical cancer patients. Inter-rater contour variability was comparable between TRUS and MR images. TRUS is a promising modality on its own for image-guided BT.

Highlights

  • Cervical cancer is endemic worldwide, affecting over half a million women every year according to the World Health Organization [1]

  • Analysis of MR images (MRI) and trans-rectal ultrasound (TRUS) contours revealed that TRUS High-risk clinical target volume (CTVHR) volumes were statistically smaller than the respective MRI contoured volumes (Table 2)

  • TRUS CTVHR thickness was found to be consistently smaller than MRI contours in all patients (Fig. 4) and in both contouring phases

Read more

Summary

Introduction

Cervical cancer is endemic worldwide, affecting over half a million women every year according to the World Health Organization [1]. This is a particular major health problem in developing countries where 90% of cervical cancer deaths occur [1]. Chemoradiation plus brachytherapy (BT) is the standard treatment modality for locally-advanced cervical cancer. Brachytherapy plays an important role in cervical cancer treatment, as survival and other oncological outcomes have been shown to be inferior whenever this is Mendez et al Radiation Oncology (2020) 15:73 therapy omitted [4]. Over the two last decade, imageguided BT based on magnetic resonance (MR) images (MRI) has become the recommended standard technology for treatment of cervical cancer [5]. The availability of MR scanners for BT planning are limited to a minority of centres worldwide

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call